Patient and public involvement in the benefit-risk assessment and decision concerning health products : position of the Scientific Advisory Board of the French National Agency for Medicines and Health Products Safety (ANSM)

Belgodère, Laëtitia; Pougheon Bertrand, Dominique; Jaulent, Marie Christine; Rabeharisoa, Vololona; Janssens, Walter; Rollason, Victoria; Barbot, Janine; Vernant, Jean Paul; Oualikene Gonin, Wahiba; Maison, Patrick; Ankri, Joel; Scientific Advisory Board of the ANSM

doi:10.1136/bmjgh-2023-011966

Scientific article

English

Patient and public involvement in the benefit-risk assessment and decision concerning health products : position of the Scientific Advisory Board of the French National Agency for Medicines and Health Products Safety (ANSM)

ContributorsBelgodère, Laëtitia

; Pougheon Bertrand, Dominique; Jaulent, Marie Christine; Rabeharisoa, Vololona; Janssens, Walter; Rollason, Victoria; Barbot, Janine; Vernant, Jean Paul; Oualikene Gonin, Wahiba; Maison, Patrick; Ankri, Joel; Scientific Advisory Board of the ANSM

Published inBMJ global health, vol. 8, no. 5, e011966

Publication date2023-05

Keywords

Health policy
Health systems evaluation
Public health
Treatment
Humans
Risk Assessment
Public Health

Affiliation entities

Faculté de médecine / Section de médecine clinique / Département d'anesthésiologie, pharmacologie, soins intensifs et urgences

Research groups

Pharmaco-omiques et médecine de précision (1003)

Citation (ISO format)

BELGODÈRE, Laëtitia et al. Patient and public involvement in the benefit-risk assessment and decision concerning health products : position of the Scientific Advisory Board of the French National Agency for Medicines and Health Products Safety (ANSM). In: BMJ global health, 2023, vol. 8, n° 5, p. e011966. doi: 10.1136/bmjgh-2023-011966